title: Reply to Roberto Iacovelli, Walter Artibani, and Giampaolo Tortora's Letter to the Editor re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol 2017;71:970-8.
authors.affiliation: Monash University and Eastern Health, Box Hill, Victoria, Australia. Electronic address: ian.davis@monash.edu.
authors.forename: Ian D
authors.initials: ID
authors.lastname: Davis
authors.affiliation: Monash University and Eastern Health, Box Hill, Victoria, Australia.
authors.forename: Carmel
authors.initials: C
authors.lastname: Pezaro
authors.affiliation: Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
authors.forename: Wanling
authors.initials: W
authors.lastname: Xie
authors.affiliation: Dana Farber Cancer Institute, Boston, MA, USA.
authors.forename: Toni K
authors.initials: TK
authors.lastname: Choueiri
authors.affiliation: Tom Baker Cancer Center, University of Calgary, Calgary, AB, Canada.
authors.forename: Daniel Y C
authors.initials: DYC
authors.lastname: Heng
mesh_terms: D002292:Carcinoma, Renal Cell; D016208:Databases, Factual; D006801:Humans; D007680:Kidney Neoplasms; D016609:Neoplasms, Second Primary; D011379:Prognosis